ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Abstracts tagged "remission and tofacitnib"

  • Abstract Number: 1977 • ACR/ARHP Annual Meeting 2013

    Remission At 3 Or 6 Months and Radiographic Non-Progression At 12 Months In Methotrexate-Naïve Rheumatoid Arthritis Patients Treated With Tofacitinib Or Methotrexate: A Post-Hoc Analysis Of The ORAL Start Trial

    V. Strand1, D. van der Heijde2, R. Landewe3, E. B. Lee4, B. Wilkinson5, S. H. Zwillich5, J. Bradley5, C. Mebus5, B. Benda6 and D. Gruben5, 1Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 4Seoul National University, Seoul, South Korea, 5Pfizer Inc, Groton, CT, 6Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of RA. The importance of “treat to target” in RA to attain…

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology